Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  VERTEX PHARMACEUTICALS INC / MA
 2. Date of Event Requiring Statement (Month/Day/Year)
01/25/2006		 3. Issuer Name and Ticker or Trading Symbol
Altus Pharmaceuticals Inc. [ALTU]
(Last)
(First)
(Middle)
130 WAVERLY STREET		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

CAMBRIDGE, MA 02139		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Redeemable Preferred Stock 450,000
D
 
Common Stock 466,680 (1) (2)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants 09/26/2001 02/01/2009 Common Stock 1,962,494 (1) $ 5.64 D  
Series A Prefered Stock 09/26/2001 01/31/2006(3) Common Stock 381,596 (1) $ 5.73 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
VERTEX PHARMACEUTICALS INC / MA
130 WAVERLY STREET
CAMBRIDGE, MA 02139		     X    

Signatures

Kenneth S. Boger, Attorney-In-Fact 01/25/2006
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) After taking into account a 1:2.293 reverse stock split of the Issuer's Common Stock and, in the case of Warrants and the Series A Preferred Stock, adjustments to the applicable exercise price or conversion price, respectively, as a result of such reverse stock split.
(2) Includes 30,528 (post-split) shares held by Joshua S. Boger, the President and Chief Executive Officer of Vertex Pharmaceuticals Incorporated, for which Vertex disclaims beneficial ownership.
(3) Reflecting the anticipated date of the closing of the Issuer's initial public offering of common stock, upon which the Series A Preferred Stock will convert into the indicated number of shares of Common Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.